NCT05297903View on ClinicalTrials.gov

XmAb20717 in Advanced Biliary Tract Cancers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

December 2, 2026

Study Completion Date

December 2, 2026

Conditions
Biliary Tract Cancer
Interventions
DRUG

XmAb20717

10mg/kg IV

Trial Locations (1)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Xencor, Inc.

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER